Last 12 months
Inside the activity.
0 purchase rows · 46 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 7 |
| Dec 2025 | 0 | 9 |
| Jan 2026 | 0 | 2 |
| Feb 2026 | 0 | 1 |
| Mar 2026 | 0 | 1 |
| Apr 2026 | 0 | 1 |
| May 2026 | 0 | 2 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 15 |
| Aug 2026 | 0 | 5 |
| Sep 2026 | 0 | 2 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 08, 2018 Filed Nov 9, 2018 21:21 UTC |
BIENAIME JEAN JACQUESDirector
|
PurchaseCommon Stock | 500 | $68.91 | $34,455.00 |
DisclosureSEC source: 0001209191-18-057953 · doc4.xml · nonDerivative · entry 2 BIENAIME JEAN JACQUES · CIK 0001221590 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,668 Read SEC document |
| November 08, 2018 Filed Nov 9, 2018 21:21 UTC |
BIENAIME JEAN JACQUESDirector
|
PurchaseCommon Stock | 500 | $68.62 | $34,310.00 |
DisclosureSEC source: 0001209191-18-057953 · doc4.xml · nonDerivative · entry 1 BIENAIME JEAN JACQUES · CIK 0001221590 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,168 Read SEC document |
| October 03, 2018 Filed Oct 5, 2018 20:30 UTC |
Trower PaulPrincipal Accounting Officer
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $17.79 | $0.00 |
DisclosureSEC source: 0001209191-18-054389 · doc4.xml · derivative · entry 3 Trower Paul · CIK 0001642041 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,187 Underlying: Common Stock · 10,000 shares Expires 2019-01-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Beginning January 19, 2012, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years Read SEC document |
| October 03, 2018 Filed Oct 5, 2018 20:30 UTC |
Trower PaulPrincipal Accounting Officer
|
SaleCommon Stock | 10,000 | $70.00 | $700,000.00 |
DisclosureSEC source: 0001209191-18-054389 · doc4.xml · nonDerivative · entry 2 Trower Paul · CIK 0001642041 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,172 F1 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. F2 · balance_after: This includes an 5,619 aggregate of shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| October 03, 2018 Filed Oct 5, 2018 20:30 UTC |
Trower PaulPrincipal Accounting Officer
|
Exercise / conversionCommon Stock | 10,000 | $17.79 | $177,900.00 |
DisclosureSEC source: 0001209191-18-054389 · doc4.xml · nonDerivative · entry 1 Trower Paul · CIK 0001642041 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,172 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 03, 2018 Filed Oct 5, 2018 20:29 UTC |
SWAIN PAULA JEVP, Human Resources
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $18.32 | $0.00 |
DisclosureSEC source: 0001209191-18-054387 · doc4.xml · derivative · entry 3 SWAIN PAULA J · CIK 0001236934 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,782 Underlying: Common Stock · 10,000 shares Expires 2020-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Beginning February 9, 2013, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years. Read SEC document |
| October 03, 2018 Filed Oct 5, 2018 20:29 UTC |
SWAIN PAULA JEVP, Human Resources
|
SaleCommon Stock | 10,000 | $70.00 | $700,000.00 |
DisclosureSEC source: 0001209191-18-054387 · doc4.xml · nonDerivative · entry 2 SWAIN PAULA J · CIK 0001236934 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,324 F1 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · balance_after: Includes an aggregate of 8,026 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| October 03, 2018 Filed Oct 5, 2018 20:29 UTC |
SWAIN PAULA JEVP, Human Resources
|
Exercise / conversionCommon Stock | 10,000 | $18.32 | $183,200.00 |
DisclosureSEC source: 0001209191-18-054387 · doc4.xml · nonDerivative · entry 1 SWAIN PAULA J · CIK 0001236934 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,324 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 03, 2018 Filed Oct 5, 2018 20:23 UTC |
Flannelly Barry PEVP & General Manager US
|
SaleCommon Stock | 1,000 | $70.00 | $70,000.00 |
DisclosureSEC source: 0001209191-18-054382 · doc4.xml · nonDerivative · entry 1 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,427 F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. F2 · balance_after: Includes an aggregate of 8,026 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| September 28, 2018 Filed Oct 2, 2018 21:06 UTC |
BAKER BROS. ADVISORS LPDirector · 10% owner
14159, L.P.Director · 10% owner
667, L.P.Director · 10% owner
Baker Bros. Advisors (GP) LLCDirector · 10% owner
Baker Brothers Life Sciences LPDirector · 10% owner
BAKER FELIXDirector · 10% owner
BAKER JULIANDirector · 10% owner
|
GrantCommon Stock | 275 | $69.08 | $18,997.00 |
DisclosureSEC source: 0001638599-18-001150 · doc4_5715.xml · nonDerivative · entry 6 BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner 14159, L.P. · CIK 0001551138 · Director · 10% owner 667, L.P. · CIK 0001551139 · Director · 10% owner Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner BAKER FELIX · CIK 0001087940 · Director · 10% owner BAKER JULIAN · CIK 0001087939 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 810,564 F4 · ownership.nature: 275 shares of common stock (the "Common Stock") issued to Julian C. Baker pursuant to the Issuer's Amended and Restated 2010 Stock Incentive Plan (the "Stock Incentive Plan") in lieu of director retainer fees of $19,000. The shares of Common Stock are fully vested. Julian C. Baker serves on the Issuer's Board of Directors (the "Board") as a representative of the Funds (as defined below). F5 · ownership.nature: Pursuant to the policies of Baker Bros. Advisors LP (the "Adviser"), Julian C. Baker does not have any right to the pecuniary interest in the Issuer's securities issued in lieu of director retainer fees and the Funds (as defined below) are entitled to an indirect proportionate pecuniary interest in the securities. 667, L.P. ("667"), Baker Brothers Life Sciences, L.P. ("Life Sciences") and 14159, L.P. ("14159", and together with 667, and Life Sciences, the "Funds") each owns an indirect proportionate pecuniary interest in the shares of Common Stock. Solely as a result of their ownership interest in the general partners of the general partners of the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the shares of Common Stock issued in lieu of director retainer fees (ie. no direct pecuniary interest). F8 · ownership.nature: As a result of Felix J. Baker's and Julian C. Baker's ownership interest in 14159 Capital (GP), LLC, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in 810,564 shares of common stock of the Issuer beneficially owned by 14159, a limited partnership of which the sole general partner is 14159 Capital, L.P., a limited partnership of which the sole general partner is 14159 Capital (GP), LLC, due to 14159 Capital, L.P.'s right to receive an allocation of a portion of the profits from 14159. Includes beneficial ownership of 2,858 shares issued pursuant to the Stock Incentive Plan in lieu of director retainer fees and 115,000 shares received previously from exercise of 115,000 stock options of the Issuer that were issued to Julian C. Baker in his capacity as a director of the Issuer, of which the fund may be deemed to own a portion. F9 · ownership.nature: The Adviser serves as the Investment Adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are Managing Members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds. F10 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose. F11 · ownership.nature: The 275 shares are reported for each of the Funds as each has an indirect pecuniary interest. Read SEC document |
| September 28, 2018 Filed Oct 2, 2018 21:06 UTC |
BAKER BROS. ADVISORS LPDirector · 10% owner
14159, L.P.Director · 10% owner
667, L.P.Director · 10% owner
Baker Bros. Advisors (GP) LLCDirector · 10% owner
Baker Brothers Life Sciences LPDirector · 10% owner
BAKER FELIXDirector · 10% owner
BAKER JULIANDirector · 10% owner
|
GrantCommon Stock | 275 | $69.08 | $18,997.00 |
DisclosureSEC source: 0001638599-18-001150 · doc4_5715.xml · nonDerivative · entry 5 BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner 14159, L.P. · CIK 0001551138 · Director · 10% owner 667, L.P. · CIK 0001551139 · Director · 10% owner Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner BAKER FELIX · CIK 0001087940 · Director · 10% owner BAKER JULIAN · CIK 0001087939 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 29,268,495 F4 · ownership.nature: 275 shares of common stock (the "Common Stock") issued to Julian C. Baker pursuant to the Issuer's Amended and Restated 2010 Stock Incentive Plan (the "Stock Incentive Plan") in lieu of director retainer fees of $19,000. The shares of Common Stock are fully vested. Julian C. Baker serves on the Issuer's Board of Directors (the "Board") as a representative of the Funds (as defined below). F5 · ownership.nature: Pursuant to the policies of Baker Bros. Advisors LP (the "Adviser"), Julian C. Baker does not have any right to the pecuniary interest in the Issuer's securities issued in lieu of director retainer fees and the Funds (as defined below) are entitled to an indirect proportionate pecuniary interest in the securities. 667, L.P. ("667"), Baker Brothers Life Sciences, L.P. ("Life Sciences") and 14159, L.P. ("14159", and together with 667, and Life Sciences, the "Funds") each owns an indirect proportionate pecuniary interest in the shares of Common Stock. Solely as a result of their ownership interest in the general partners of the general partners of the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the shares of Common Stock issued in lieu of director retainer fees (ie. no direct pecuniary interest). F7 · ownership.nature: As a result of Felix J. Baker's and Julian C. Baker's ownership interest in Baker Brothers Life Sciences Capital (GP), LLC, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in 29,268,495 shares of common stock of the Issuer beneficially owned by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences. Includes beneficial ownership of 2,858 shares issued pursuant to the Stock Incentive Plan in lieu of director retainer fees and 115,000 shares received previously from exercise of 115,000 stock options of the Issuer that were issued to Julian C. Baker in his capacity as a director of the Issuer, of which the fund may be deemed to own a portion. F9 · ownership.nature: The Adviser serves as the Investment Adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are Managing Members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds. F10 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose. F11 · ownership.nature: The 275 shares are reported for each of the Funds as each has an indirect pecuniary interest. Read SEC document |
| September 28, 2018 Filed Oct 2, 2018 21:06 UTC |
BAKER BROS. ADVISORS LPDirector · 10% owner
14159, L.P.Director · 10% owner
667, L.P.Director · 10% owner
Baker Bros. Advisors (GP) LLCDirector · 10% owner
Baker Brothers Life Sciences LPDirector · 10% owner
BAKER FELIXDirector · 10% owner
BAKER JULIANDirector · 10% owner
|
GrantCommon Stock | 275 | $69.08 | $18,997.00 |
DisclosureSEC source: 0001638599-18-001150 · doc4_5715.xml · nonDerivative · entry 4 BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner 14159, L.P. · CIK 0001551138 · Director · 10% owner 667, L.P. · CIK 0001551139 · Director · 10% owner Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner BAKER FELIX · CIK 0001087940 · Director · 10% owner BAKER JULIAN · CIK 0001087939 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 4,407,966 F4 · ownership.nature: 275 shares of common stock (the "Common Stock") issued to Julian C. Baker pursuant to the Issuer's Amended and Restated 2010 Stock Incentive Plan (the "Stock Incentive Plan") in lieu of director retainer fees of $19,000. The shares of Common Stock are fully vested. Julian C. Baker serves on the Issuer's Board of Directors (the "Board") as a representative of the Funds (as defined below). F5 · ownership.nature: Pursuant to the policies of Baker Bros. Advisors LP (the "Adviser"), Julian C. Baker does not have any right to the pecuniary interest in the Issuer's securities issued in lieu of director retainer fees and the Funds (as defined below) are entitled to an indirect proportionate pecuniary interest in the securities. 667, L.P. ("667"), Baker Brothers Life Sciences, L.P. ("Life Sciences") and 14159, L.P. ("14159", and together with 667, and Life Sciences, the "Funds") each owns an indirect proportionate pecuniary interest in the shares of Common Stock. Solely as a result of their ownership interest in the general partners of the general partners of the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the shares of Common Stock issued in lieu of director retainer fees (ie. no direct pecuniary interest). F6 · ownership.nature: As a result of Felix J. Baker's and Julian C. Baker's ownership interest in Baker Biotech Capital (GP), LLC, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in 4,407,966 shares of common stock of the Issuer beneficially owned by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP),LLC, due to Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667. Includes beneficial ownership of 2,858 shares issued pursuant to the Stock Incentive Plan in lieu of director retainer fees and 115,000 shares received previously from exercise of 115,000 stock options of the Issuer that were issued to Julian C. Baker in his capacity as a director of the Issuer, of which the fund may be deemed to own a portion. F9 · ownership.nature: The Adviser serves as the Investment Adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are Managing Members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds. F10 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose. F11 · ownership.nature: The 275 shares are reported for each of the Funds as each has an indirect pecuniary interest. Read SEC document |
| September 28, 2018 Filed Oct 2, 2018 20:19 UTC |
FOUSE JACQUALYN ADirector
|
GrantCommon Stock | 180 | $69.08 | $12,434.40 |
DisclosureSEC source: 0001209191-18-053114 · doc4.xml · nonDerivative · entry 1 FOUSE JACQUALYN A · CIK 0001405288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 516 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. Read SEC document |
| September 28, 2018 Filed Oct 2, 2018 20:27 UTC |
BROOKE PAUL ADirector
|
GrantCommon Stock | 343 | $69.08 | $23,694.44 |
DisclosureSEC source: 0001209191-18-053138 · doc4.xml · nonDerivative · entry 1 BROOKE PAUL A · CIK 0001175940 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 198,556 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. Read SEC document |
| September 28, 2018 Filed Oct 2, 2018 20:11 UTC |
BIENAIME JEAN JACQUESDirector
|
GrantCommon Stock | 209 | $69.08 | $14,437.72 |
DisclosureSEC source: 0001209191-18-053090 · doc4.xml · nonDerivative · entry 1 BIENAIME JEAN JACQUES · CIK 0001221590 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,668 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. Read SEC document |
| September 28, 2018 Filed Oct 2, 2018 20:15 UTC |
DIXON WENDY LDirector
|
GrantCommon Stock | 235 | $69.08 | $16,233.80 |
DisclosureSEC source: 0001209191-18-053099 · doc4.xml · nonDerivative · entry 1 DIXON WENDY L · CIK 0001202283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,944 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. Read SEC document |
| September 04, 2018 Filed Sep 6, 2018 20:30 UTC |
SWAIN PAULA JEVP, Human Resources
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $18.32 | $0.00 |
DisclosureSEC source: 0001209191-18-049827 · doc4.xml · derivative · entry 3 SWAIN PAULA J · CIK 0001236934 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,782 Underlying: Common Stock · 10,000 shares Expires 2020-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Beginning February 9, 2013, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years. Read SEC document |
| September 04, 2018 Filed Sep 6, 2018 20:30 UTC |
SWAIN PAULA JEVP, Human Resources
|
SaleCommon Stock | 10,000 | $73.21 | $732,100.00 |
DisclosureSEC source: 0001209191-18-049827 · doc4.xml · nonDerivative · entry 2 SWAIN PAULA J · CIK 0001236934 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,324 F1 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: Represents weighted average sale price. Actual sale prices ranged from $72.84 - $73.89. F3 · price: Reporting person undertakes to provide upon request by Securites and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within range indicated. F4 · balance_after: Includes an aggregate of 8,026 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| September 04, 2018 Filed Sep 6, 2018 20:30 UTC |
SWAIN PAULA JEVP, Human Resources
|
Exercise / conversionCommon Stock | 10,000 | $18.32 | $183,200.00 |
DisclosureSEC source: 0001209191-18-049827 · doc4.xml · nonDerivative · entry 1 SWAIN PAULA J · CIK 0001236934 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,324 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 21, 2018 Filed Aug 22, 2018 20:02 UTC |
SWAIN PAULA JEVP, Human Resources
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $18.32 | $0.00 |
DisclosureSEC source: 0001209191-18-047908 · doc4.xml · derivative · entry 3 SWAIN PAULA J · CIK 0001236934 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,782 Underlying: Common Stock · 10,000 shares Expires 2020-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Beginning February 9, 2013, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years. Read SEC document |
| August 21, 2018 Filed Aug 22, 2018 20:02 UTC |
SWAIN PAULA JEVP, Human Resources
|
SaleCommon Stock | 10,000 | $70.00 | $700,000.00 |
DisclosureSEC source: 0001209191-18-047908 · doc4.xml · nonDerivative · entry 2 SWAIN PAULA J · CIK 0001236934 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,324 F1 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · balance_after: Includes an aggregate of 8,026 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| August 21, 2018 Filed Aug 22, 2018 20:02 UTC |
SWAIN PAULA JEVP, Human Resources
|
Exercise / conversionCommon Stock | 10,000 | $18.32 | $183,200.00 |
DisclosureSEC source: 0001209191-18-047908 · doc4.xml · nonDerivative · entry 1 SWAIN PAULA J · CIK 0001236934 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,324 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 16, 2018 Filed Jul 18, 2018 21:22 UTC |
Wenqing YaoEVP, Head of Discovery Chem
|
Tax withholdingCommon Stock | 430 | $70.19 | $30,181.70 |
DisclosureSEC source: 0001209191-18-043120 · doc4.xml · nonDerivative · entry 1 Wenqing Yao · CIK 0001624033 · EVP, Head of Discovery Chem 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,217 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. F2 · balance_after: Includes an aggregate of 8,026 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| July 16, 2018 Filed Jul 18, 2018 21:16 UTC |
Trower PaulPrincipal Accounting Officer
|
Tax withholdingCommon Stock | 196 | $70.19 | $13,757.24 |
DisclosureSEC source: 0001209191-18-043115 · doc4.xml · nonDerivative · entry 1 Trower Paul · CIK 0001642041 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,172 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. F2 · balance_after: Includes an aggregate of 2,925 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| July 16, 2018 Filed Jul 18, 2018 21:12 UTC |
SWAIN PAULA JEVP, Human Resources
|
Tax withholdingCommon Stock | 639 | $70.19 | $44,851.41 |
DisclosureSEC source: 0001209191-18-043111 · doc4.xml · nonDerivative · entry 1 SWAIN PAULA J · CIK 0001236934 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,324 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. F2 · balance_after: Includes an aggregate of 8,026 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| July 16, 2018 Filed Jul 18, 2018 21:06 UTC |
Stein Steven HEVP & Chief Medical Officer
|
Tax withholdingCommon Stock | 577 | $70.19 | $40,499.63 |
DisclosureSEC source: 0001209191-18-043106 · doc4.xml · nonDerivative · entry 1 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,620 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. F2 · balance_after: Includes an aggregate of 8,026 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| July 16, 2018 Filed Jul 18, 2018 20:28 UTC |
Huber Reid MEVP, Chief Scientific Officer
|
Tax withholdingCommon Stock | 448 | $70.19 | $31,445.12 |
DisclosureSEC source: 0001209191-18-043040 · doc4.xml · nonDerivative · entry 1 Huber Reid M · CIK 0001607052 · EVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,571 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. F2 · balance_after: Includes an aggregate of 8,026 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| July 16, 2018 Filed Jul 18, 2018 20:25 UTC |
Hoppenot HerveDirector · Chairman / CEO · President
|
Tax withholdingCommon Stock | 2,359 | $70.19 | $165,578.21 |
DisclosureSEC source: 0001209191-18-043035 · doc4.xml · nonDerivative · entry 1 Hoppenot Herve · CIK 0001596492 · Director · Chairman / CEO · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184,766 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. F2 · balance_after: Includes an aggregate of 164,837 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| July 16, 2018 Filed Jul 18, 2018 20:09 UTC |
Flannelly Barry PEVP & General Manager US
|
Tax withholdingCommon Stock | 430 | $70.19 | $30,181.70 |
DisclosureSEC source: 0001209191-18-043025 · doc4.xml · nonDerivative · entry 1 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,427 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. F2 · balance_after: Includes an aggregate of 8,026 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| July 16, 2018 Filed Jul 18, 2018 20:12 UTC |
GRYSKA DAVID WExecutive Vice President, CFO
|
Tax withholdingCommon Stock | 455 | $70.19 | $31,936.45 |
DisclosureSEC source: 0001209191-18-043028 · doc4.xml · nonDerivative · entry 1 GRYSKA DAVID W · CIK 0001202335 · Executive Vice President, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,235 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. F2 · balance_after: Includes an aggregate of 8,026 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| July 09, 2018 Filed Jul 11, 2018 20:41 UTC |
SWAIN PAULA JEVP, Human Resources
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $18.32 | $0.00 |
DisclosureSEC source: 0001209191-18-042343 · doc4.xml · derivative · entry 3 SWAIN PAULA J · CIK 0001236934 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,782 Underlying: Common Stock · 10,000 shares Expires 2020-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Beginning February 9, 2013, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years Read SEC document |
| July 09, 2018 Filed Jul 11, 2018 20:41 UTC |
SWAIN PAULA JEVP, Human Resources
|
SaleCommon Stock | 10,000 | $71.11 | $711,100.00 |
DisclosureSEC source: 0001209191-18-042343 · doc4.xml · nonDerivative · entry 2 SWAIN PAULA J · CIK 0001236934 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,963 F1 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: Represents weighted average sale price. Actual sale prices ranged from $70.27 - $71.68. F3 · price: Reporting person undertakes to provide upon request by Securites and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within range indicated. F4 · balance_after: Includes an aggregate of 9,415 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| July 09, 2018 Filed Jul 11, 2018 20:41 UTC |
SWAIN PAULA JEVP, Human Resources
|
Exercise / conversionCommon Stock | 10,000 | $18.32 | $183,200.00 |
DisclosureSEC source: 0001209191-18-042343 · doc4.xml · nonDerivative · entry 1 SWAIN PAULA J · CIK 0001236934 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,963 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 09, 2018 Filed Jul 11, 2018 20:39 UTC |
Iyengar Vijay KEVP GPS, BD, & Licensing
|
SaleCommon Stock | 606 | $71.34 | $43,232.04 |
DisclosureSEC source: 0001209191-18-042339 · doc4.xml · nonDerivative · entry 1 Iyengar Vijay K · CIK 0001670000 · EVP GPS, BD, & Licensing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,103 F1 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. F2 · balance_after: Includes an aggregate of 7,270 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| July 05, 2018 Filed Jul 5, 2018 21:12 UTC |
GRYSKA DAVID WExecutive Vice President, CFO
|
Tax withholdingCommon Stock | 280 | $68.28 | $19,118.40 |
DisclosureSEC source: 0001209191-18-041743 · doc4.xml · nonDerivative · entry 1 GRYSKA DAVID W · CIK 0001202335 · Executive Vice President, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,690 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. F2 · balance_after: Includes an aggregate of 9,415 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| July 05, 2018 Filed Jul 5, 2018 21:04 UTC |
Huber Reid MEVP, Chief Scientific Officer
|
Tax withholdingCommon Stock | 284 | $68.28 | $19,391.52 |
DisclosureSEC source: 0001209191-18-041730 · doc4.xml · nonDerivative · entry 1 Huber Reid M · CIK 0001607052 · EVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,019 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. F2 · balance_after: Includes an aggregate of 9,415 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| July 05, 2018 Filed Jul 5, 2018 21:18 UTC |
Hoppenot HerveDirector · Chairman / CEO · President
|
Tax withholdingCommon Stock | 1,532 | $68.28 | $104,604.96 |
DisclosureSEC source: 0001209191-18-041748 · doc4.xml · nonDerivative · entry 1 Hoppenot Herve · CIK 0001596492 · Director · Chairman / CEO · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,125 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. F2 · balance_after: Includes an aggregate of 170,238 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| July 05, 2018 Filed Jul 5, 2018 20:58 UTC |
Iyengar Vijay KEVP GPS, BD, & Licensing
|
Tax withholdingCommon Stock | 273 | $68.28 | $18,640.44 |
DisclosureSEC source: 0001209191-18-041719 · doc4.xml · nonDerivative · entry 1 Iyengar Vijay K · CIK 0001670000 · EVP GPS, BD, & Licensing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,709 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. F2 · balance_after: Includes an aggregate of 7,270 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| July 05, 2018 Filed Jul 5, 2018 20:49 UTC |
Flannelly Barry PEVP & General Manager US
|
Tax withholdingCommon Stock | 273 | $68.28 | $18,640.44 |
DisclosureSEC source: 0001209191-18-041702 · doc4.xml · nonDerivative · entry 1 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,857 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. F2 · balance_after: Includes an aggregate of 9,415 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| July 05, 2018 Filed Jul 5, 2018 20:45 UTC |
Stein Steven HEVP & Chief Medical Officer
|
Tax withholdingCommon Stock | 262 | $68.28 | $17,889.36 |
DisclosureSEC source: 0001209191-18-041685 · doc4.xml · nonDerivative · entry 1 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,197 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. F2 · balance_after: Includes an aggregate of 9,415 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| July 05, 2018 Filed Jul 5, 2018 20:28 UTC |
SWAIN PAULA JEVP, Human Resources
|
Tax withholdingCommon Stock | 404 | $68.28 | $27,585.12 |
DisclosureSEC source: 0001209191-18-041628 · doc4.xml · nonDerivative · entry 1 SWAIN PAULA J · CIK 0001236934 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,963 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. F2 · balance_after: Includes an aggregate of 9,415 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| July 05, 2018 Filed Jul 5, 2018 20:22 UTC |
Wenqing YaoEVP, Head of Discovery Chem
|
Tax withholdingCommon Stock | 273 | $68.28 | $18,640.44 |
DisclosureSEC source: 0001209191-18-041610 · doc4.xml · nonDerivative · entry 1 Wenqing Yao · CIK 0001624033 · EVP, Head of Discovery Chem 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,647 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. F2 · balance_after: Includes an aggregate of 9,415 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| July 05, 2018 Filed Jul 5, 2018 20:24 UTC |
Trower PaulPrincipal Accounting Officer
|
Tax withholdingCommon Stock | 101 | $68.28 | $6,896.28 |
DisclosureSEC source: 0001209191-18-041613 · doc4.xml · nonDerivative · entry 2 Trower Paul · CIK 0001642041 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,368 F3 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. Read SEC document |
| July 02, 2018 Filed Jul 5, 2018 21:12 UTC |
GRYSKA DAVID WExecutive Vice President, CFO
|
GrantEmployee Stock Option (right to buy) · Derivative | 22,772 | $0.00 Strike: $68.62 | $0.00 |
DisclosureSEC source: 0001209191-18-041743 · doc4.xml · derivative · entry 2 GRYSKA DAVID W · CIK 0001202335 · Executive Vice President, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,772 Underlying: Common Stock · 22,772 shares Expires 2028-07-01 F3 · derivative.exercise_date: Beginning July 2, 2018, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Read SEC document |
| July 02, 2018 Filed Jul 5, 2018 21:04 UTC |
Huber Reid MEVP, Chief Scientific Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 22,772 | $0.00 Strike: $68.62 | $0.00 |
DisclosureSEC source: 0001209191-18-041730 · doc4.xml · derivative · entry 2 Huber Reid M · CIK 0001607052 · EVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,772 Underlying: Common Stock · 22,772 shares Expires 2028-07-01 F3 · derivative.exercise_date: Beginning July 2, 2018, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Read SEC document |
| July 02, 2018 Filed Jul 5, 2018 21:18 UTC |
Hoppenot HerveDirector · Chairman / CEO · President
|
GrantEmployee Stock Option (right to buy) · Derivative | 88,557 | $0.00 Strike: $68.62 | $0.00 |
DisclosureSEC source: 0001209191-18-041748 · doc4.xml · derivative · entry 3 Hoppenot Herve · CIK 0001596492 · Director · Chairman / CEO · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,557 Underlying: Common Stock · 88,557 shares Expires 2028-07-01 F4 · derivative.exercise_date: Beginning July 2, 2018, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Read SEC document |
| July 02, 2018 Filed Jul 5, 2018 20:58 UTC |
Iyengar Vijay KEVP GPS, BD, & Licensing
|
GrantEmployee Stock Option (right to buy) · Derivative | 22,772 | $0.00 Strike: $68.62 | $0.00 |
DisclosureSEC source: 0001209191-18-041719 · doc4.xml · derivative · entry 2 Iyengar Vijay K · CIK 0001670000 · EVP GPS, BD, & Licensing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,772 Underlying: Common Stock · 22,772 shares Expires 2018-07-01 F3 · derivative.exercise_date: Beginning July 2, 2018, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Read SEC document |
| July 02, 2018 Filed Jul 5, 2018 20:53 UTC |
Pasquale Maria EEVP & General Counsel
|
GrantEmployee Stock Option (right to buy) · Derivative | 22,772 | $0.00 Strike: $68.62 | $0.00 |
DisclosureSEC source: 0001209191-18-041712 · doc4.xml · derivative · entry 1 Pasquale Maria E · CIK 0001736295 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,772 Underlying: Common Stock · 22,772 shares Expires 2028-07-01 F1 · derivative.exercise_date: Beginning July 2, 2018, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Read SEC document |
| July 02, 2018 Filed Jul 5, 2018 20:49 UTC |
Flannelly Barry PEVP & General Manager US
|
GrantEmployee Stock Option (right to buy) · Derivative | 22,772 | $0.00 Strike: $68.62 | $0.00 |
DisclosureSEC source: 0001209191-18-041702 · doc4.xml · derivative · entry 2 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,772 Underlying: Common Stock · 22,772 shares Expires 2028-07-01 F3 · derivative.exercise_date: Beginning July 2, 2018, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Read SEC document |
| July 02, 2018 Filed Jul 5, 2018 20:45 UTC |
Stein Steven HEVP & Chief Medical Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 22,772 | $0.00 Strike: $68.62 | $0.00 |
DisclosureSEC source: 0001209191-18-041685 · doc4.xml · derivative · entry 2 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,772 Underlying: Common Stock · 22,772 shares Expires 2028-07-01 F3 · derivative.exercise_date: Beginning July 2, 2018, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.